A Dose Block-randomized, Double-blind, Placebo Controlled, Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of DWP10292 and Ursodeoxycholic Acid in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs DWP 10292 (Primary) ; Ursodeoxycholic acid
- Indications Non-alcoholic fatty liver disease
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 01 Jun 2016 Status changed from active, no longer recruiting to completed.
- 26 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
- 09 Dec 2015 New trial record